27465797|t|Activation of general control nonderepressible 2 kinase protects human glomerular endothelial cells from harmful high-glucose - induced molecular pathways
27465797|a|Considering the referred beneficial effects of protein restriction on diabetic nephropathy (DN) and the role of renal endothelium in its pathogenesis, we evaluated the effect of general control nonderepressible 2 (GCN2) kinase activation, a sensor of amino acid deprivation, on known detrimental molecular pathways in primary human glomerular endothelial cells (GEnC). GEnC were cultured under normal or high -glucose conditions in the presence or not of the GCN2 kinase activator, tryptophanol. Glucose transporter 1 (GLUT1) expression was assessed by western blotting and reactive oxygen species (ROS) using a fluorogenic probe. Activities of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and protein kinase C (PKC) were assessed by commercial activity assays, sorbitol colorimetrically, methylglyoxal by ELISA and O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins by western blotting. High glucose induced GLUT1 expression, increased ROS and inhibited GAPDH. Also it increased the polyol pathway product sorbitol, PKC activity, the level of the O-GlcNAc-modified proteins that produced by the hexosamine pathway and the advanced glycation endproducts' precursor methylglyoxal. Co-treatment of GEnC with tryptophanol restored the above high-glucose - induced alterations. Activation of GCN2 kinase protects GEnC from high-glucose - induced harmful molecular pathways. By inhibiting concurrently many pathways involved in DN pathogenesis, GCN2 kinase may serve as a pharmaceutical target for the treatment of DN.
27465797	0	10	Activation	T038	UMLS:C0014429
27465797	14	55	general control nonderepressible 2 kinase	T103	UMLS:C2354171
27465797	65	70	human	T204	UMLS:C0086418
27465797	71	99	glomerular endothelial cells	T017	UMLS:C1182791
27465797	113	125	high-glucose	T033	UMLS:C0860803
27465797	136	154	molecular pathways	T038	UMLS:C1704259
27465797	202	209	protein	T103	UMLS:C0033684
27465797	225	245	diabetic nephropathy	T038	UMLS:C0011881
27465797	247	249	DN	T038	UMLS:C0011881
27465797	267	272	renal	T017	UMLS:C0022646
27465797	273	284	endothelium	T017	UMLS:C0014257
27465797	292	304	pathogenesis	T038	UMLS:C0699748
27465797	309	318	evaluated	T058	UMLS:C0220825
27465797	333	381	general control nonderepressible 2 (GCN2) kinase	T103	UMLS:C2354171
27465797	382	392	activation	T038	UMLS:C0014429
27465797	406	416	amino acid	T103	UMLS:C0002520
27465797	451	469	molecular pathways	T038	UMLS:C1704259
27465797	481	486	human	T204	UMLS:C0086418
27465797	487	515	glomerular endothelial cells	T017	UMLS:C1182791
27465797	517	521	GEnC	T017	UMLS:C1182791
27465797	524	528	GEnC	T017	UMLS:C1182791
27465797	534	542	cultured	T058	UMLS:C0430400
27465797	559	583	high -glucose conditions	T038	UMLS:C0020456
27465797	614	625	GCN2 kinase	T103	UMLS:C2354171
27465797	626	635	activator	T038	UMLS:C2247123
27465797	637	649	tryptophanol	T103	UMLS:C0526839
27465797	651	672	Glucose transporter 1	T103	UMLS:C0168458
27465797	674	679	GLUT1	T103	UMLS:C0168458
27465797	681	691	expression	T038	UMLS:C1171362
27465797	708	724	western blotting	T058	UMLS:C0005863
27465797	729	752	reactive oxygen species	T103	UMLS:C0162772
27465797	754	757	ROS	T103	UMLS:C0162772
27465797	767	784	fluorogenic probe	T103	UMLS:C0016321
27465797	786	796	Activities	T038	UMLS:C0243102
27465797	800	840	glyceraldehyde 3-phosphate dehydrogenase	T103	UMLS:C3536868
27465797	842	847	GAPDH	T103	UMLS:C3536868
27465797	853	869	protein kinase C	T103	UMLS:C0033634
27465797	871	874	PKC	T103	UMLS:C0033634
27465797	893	919	commercial activity assays	T058	UMLS:C0005507
27465797	921	929	sorbitol	T103	UMLS:C0037688
27465797	930	946	colorimetrically	T058	UMLS:C1531834
27465797	948	961	methylglyoxal	T103	UMLS:C0034338
27465797	965	970	ELISA	T058	UMLS:C0014441
27465797	975	1035	O-linked β-N-acetyl glucosamine (O-GlcNAc)-modified proteins	T103	UMLS:C0671368
27465797	1039	1055	western blotting	T058	UMLS:C0005863
27465797	1057	1069	High glucose	T033	UMLS:C0860803
27465797	1078	1083	GLUT1	T103	UMLS:C0168458
27465797	1084	1094	expression	T038	UMLS:C1171362
27465797	1106	1109	ROS	T103	UMLS:C0162772
27465797	1124	1129	GAPDH	T103	UMLS:C3536868
27465797	1153	1159	polyol	T103	UMLS:C0071629
27465797	1160	1167	pathway	T038	UMLS:C1704259
27465797	1176	1184	sorbitol	T103	UMLS:C0037688
27465797	1186	1189	PKC	T103	UMLS:C0033634
27465797	1190	1198	activity	T038	UMLS:C0243102
27465797	1217	1243	O-GlcNAc-modified proteins	T103	UMLS:C0671368
27465797	1265	1275	hexosamine	T103	UMLS:C0019477
27465797	1276	1283	pathway	T038	UMLS:C1704259
27465797	1292	1323	advanced glycation endproducts'	T103	UMLS:C0162574
27465797	1334	1347	methylglyoxal	T103	UMLS:C0034338
27465797	1365	1369	GEnC	T017	UMLS:C1182791
27465797	1375	1387	tryptophanol	T103	UMLS:C0526839
27465797	1407	1419	high-glucose	T033	UMLS:C0860803
27465797	1443	1453	Activation	T038	UMLS:C0014429
27465797	1457	1468	GCN2 kinase	T103	UMLS:C2354171
27465797	1478	1482	GEnC	T017	UMLS:C1182791
27465797	1488	1500	high-glucose	T033	UMLS:C0860803
27465797	1519	1537	molecular pathways	T038	UMLS:C1704259
27465797	1571	1579	pathways	T038	UMLS:C1704259
27465797	1592	1594	DN	T038	UMLS:C0011881
27465797	1595	1607	pathogenesis	T038	UMLS:C0699748
27465797	1609	1620	GCN2 kinase	T103	UMLS:C2354171
27465797	1636	1650	pharmaceutical	T091	UMLS:C0031336
27465797	1666	1675	treatment	T058	UMLS:C0087111
27465797	1679	1681	DN	T038	UMLS:C0011881